KP-1461

Chemical compound
  • Investigational
IdentifiersCAS Number
  • 815588-85-3
PubChem CID
  • 51003457
DrugBank
  • 05644
ChemSpider
  • 32702166
UNII
  • 3PEN569TJP
Chemical and physical dataFormulaC16H23N4O6Molar mass367.382 g·mol−13D model (JSmol)
  • Interactive image
  • CCCCCCCOC(=O)NC1=NCN(C(=O)N1)[C@H]2C[C@@H]([C@H](O2)CO)O
InChI
  • InChI=1S/C16H28N4O6/c1-2-3-4-5-6-7-25-16(24)19-14-17-10-20(15(23)18-14)13-8-11(22)12(9-21)26-13/h11-13,21-22H,2-10H2,1H3,(H2,17,18,19,23,24)/t11-,12+,13+/m0/s1
  • Key:SZWIAFVYPPMZML-YNEHKIRRSA-N

KP-161 is an experimental antiviral drug being studied for the treatment of HIV/AIDS.[1] It belongs to the class of nucleoside reverse transcriptase inhibitors.[2]

KP-1461 is a prodrug of the active antiviral agent KP-1212.[3]

References

  1. ^ "KP-1461". AIDSinfo. U.S. Department of Health and Human Services. Archived from the original on 2019-08-11. Retrieved 2018-09-04.
  2. ^ Harris K, Sergueev D, Reno J (December 2006). "The chemistry and biology of KP-1461, a selective nucleoside mutagen for HIV therapy". Retrovirology. 3 (Suppl 1): S13. doi:10.1186/1742-4690-3-S1-S13. PMC 1716920.
  3. ^ "KP-1461". DrugBank. Canadian Institutes of Health Research.
  • v
  • t
  • e
  • v
  • t
  • e
Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)
Capsid inhibitors
  • Lenacapavir (LEN)
Entry/fusion inhibitors
(Discovery and development)
Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))
Maturation inhibitors
Protease Inhibitors (PI)
(Discovery and development)
1st generation
2nd generation
Reverse-transcriptase
inhibitors (RTIs)
Nucleoside and
nucleotide (NRTI)
Non-nucleoside (NNRTI)
(Discovery and development)
1st generation
2nd generation
Combined formulations
Pharmacokinetic boosters
Experimental agents
Uncoating inhibitors
Transcription inhibitors
  • Tat antagonists
Translation inhibitors
BNAbs
Other
Failed agents
°DHHS recommended initial regimen options. ◊Formerly or rarely used agent.